Share on StockTwits

Stock analysts at JPMorgan Chase & Co. increased their target price on shares of Trivascular Technologies (NASDAQ:TRIV) from $18.00 to $20.00 in a report issued on Thursday. JPMorgan Chase & Co.’s price objective indicates a potential upside of 43.88% from the company’s current price.

Other equities research analysts have also recently issued reports about the stock. Analysts at Canaccord Genuity initiated coverage on shares of Trivascular Technologies in a research note on Monday, May 12th. They set a “buy” rating and a $20.00 price target on the stock. Separately, analysts at Stifel Nicolaus initiated coverage on shares of Trivascular Technologies in a research note on Monday, May 12th. They set a “buy” rating and a $17.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Credit Suisse initiated coverage on shares of Trivascular Technologies in a research note on Monday, May 12th. They set an “outperform” rating and a $17.00 price target on the stock.

Trivascular Technologies (NASDAQ:TRIV) traded down 1.88% on Thursday, hitting $14.09. 1,345 shares of the company’s stock traded hands. Trivascular Technologies has a 52 week low of $11.15 and a 52 week high of $17.99. The stock’s 50-day moving average is $15.26 and its 200-day moving average is $15.04. The company’s market cap is $272.3 million.

Trivascular Technologies (NASDAQ:TRIV) last released its earnings data on Wednesday, August 6th. The company reported ($0.87) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.66) by $0.21. The company had revenue of $7.80 million for the quarter, compared to the consensus estimate of $7.54 million. The company’s quarterly revenue was up 61.5% on a year-over-year basis. Analysts expect that Trivascular Technologies will post $-3.05 EPS for the current fiscal year.

Trivascular Technologies, Inc is a medical device company. The Company is developing and commercializing technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms (NASDAQ:TRIV).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.